NCI-2022-04793

A Phase 1/2 Study of BA3071 in Patients with Solid Tumors

This is a multi-center, open-label study designed to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of a drug called BA3071. Phase 2 of the study is currently recruiting patients with the following conditions: NSCLC with mutations in KRAS, STK11 and PD-L1 <1%.

Phase 2: An advanced point of testing, where they're trying to confirm if a treatment works well.

non-small cell lung cancer (NSCLC): A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

pharmacokinetics: Pharmacokinetics studies how medicines move around in the body, including how they are absorbed, distributed, broken down, and removed.

open-label: Patients know which treatments are being given to them

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05180799

Clinical Trial Site: Sinai

To see all available clinical trials click here.